Neuroprotective effects of ultra-low-molecular-weight heparin in vitro and vivo models of ischemic injury

Fundamental and Clinical Pharmacology

Volumn 25, Issue 3, 2011, Pages 300-303

  Zhang, Zhi guo ^a   Lü, Tai sheng ^a   Yuan, Hong ying ^a  

^a The 88th Hospital of PLA   (China)

Author keywords

Focal cerebral ischemia; Middle cerebral artery occlusion (MCAO); Neuroprotection; Ultra low molecular weight heparin (ULMWH)

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; SODIUM DITHIONITE; ULTRA LOW MOLECULAR WEIGHT HEPARIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ISCHEMIA; CELL DAMAGE; CONCENTRATION RESPONSE; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN; CELL SURVIVAL; CELLS, CULTURED; HEPARIN, LOW-MOLECULAR-WEIGHT; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; NEUROPROTECTIVE AGENTS; PC12 CELLS; RATS; RATS, WISTAR;

EID: 79954625159     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00845.x     Document Type: Article

References (13)

1. Warlow C.P. Epidemiology of stroke. Lancet (1998) 352(Suppl III) 1-4.
2. Samama M.M., Desnoyers P.C., Conard J., Bousser M.G. Acute ischemic stroke and heparin treatment. Thromb. Haemost. (1997) 78 173-179.
3. Quartermain D., Li Y.S., Jonas S. The Low molecular weight heparin enoxaparin reduces infarct size in a rat model of temporary focal ischemia. Cerebrovasc. Dis. (2003) 16 346-355.
4. Ma Q., Dudas B., Hejna M. et al. The blood-brain barrier accessibility of a heparin-derived oligosaccharides C3. Thromb. Res. (2002) 105 447-453.
5. Longa E.Z., Weinstain P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke (1989) 20 84-91.
6. Yamazakia M., Chibaa K., Mohri T. Differences in neuritogenic response to nitric oxiNeuroscience Letters de in PC12 and PC12h cells. Neurosci. Lett. (2006) 393 222-225.
7. Padma V., Fisher M., Moonis M. Role of heparin and low-molecular-weight heparins in the management of acute ischemic stroke. Cardiovasc. Ther. (2006) 4 405-415.
8. Culmsee C., Krieglstein J. Emerging pharmacotherapeutic strategies for the treatment of ischemic stroke. Drug Discov Today Ther Strat. (2006) 3 621-628.
9. Jonas S., Sugimori M., Llinas R. Is low molecular weight heparin a neuroprotectant? Ann. N Y Acad. Sci. (1997) 825 389-393.
10. Leculier C., Couprie N., Adeleine P. et al. The effects of high molecular weight- and low molecular weight-heparins on superoxide ion production and degranulation by human polymorphonuclear leukocytes. Thromb. Res. (1993) 69 519-531.
11. Oyanagui Y., Sato S. Heparin, a potent releasing agent of extracellular superoxide dismutase (EC-SOD C), suppresses ischaemic paw oedema in mice. Free Radic Res Commun. (1990) 9 87-99.
12. Libersan D., Khalil A., Dagenais P. The low molecular weight heparin, enoxaparin, limits infarct size at reperfusion in the dog. Cardiovasc. Res. (1998) 37 656-666.
13. Gikakis N., Khan M.M., Hiramatsu Y. et al. Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extracorporeal circulation. Circulation (1996) 94(Suppl 9) II341-II346.